Combination of CD33 antibody drug conjugates with chemotherapeutic agents

A method of treating CD33 expressing acute myeloid leukemia (AML) in a subject in need of such treatment, the method comprising:

• 1) administering an anthracycline antibiotic, and a CD33 antibody drug conjugate (ADC) in an induction period of seven days, wherein the CD33-ADC comprises a humanized 2H12 antibody and a PBD cytotoxic agent, and wherein 10 μg/kg or 20 μg/kg of the CD33-ADC is administered on day one of the induction period and 10 μg/kg of the CD33-ADC is administered on day four of the induction period;
• wherein the anthracycline antibiotic:
• 1) is cytarabine and is administered on induction days 1-7;
• or 2) is daunorubicin and is administered on induction days 1-3;
• and
• 2) after the induction period, administering the CD33-ADC and cytarabine in up to four consolidation cycles each comprising seven days, wherein the CD33-ADC is administered on day 1 of each consolidations cycle at 10 μg/kg or 20 μg/kg, and wherein cytarabine is administered on days 1, 3, and 5 of each consolidation cycles at 3 mg/m2/day.